About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: To find a complete list of Publications, please see listing here.

 

Found 151 results
2021
H. E. Heslop, Stadtmauer, E. A., Levine, J. E., Ballen, K. K., Bin Chen, Y. -, DeZern, A. E., Eapen, M., Hamadani, M., Hamilton, B. K., Hari, P., Jones, R. J., Logan, B. R., Kean, L. S., Leifer, E. S., Locke, F. L., Maziarz, R. T., Nemecek, E. R., Pasquini, M., Phelan, R., Riches, M. L., Shaw, B. E., Walters, M. C., Foley, A., Devine, S. M., and Horowitz, M. M., “Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.”, Transplant Cell Ther, vol. 27, no. 11, pp. 885-907, 2021.
E. D. Warlick, Ustun, C., Andreescu, A., Bonagura, A. F., Brunner, A., Chandra, A. B., Foran, J. M., Juckett, M. B., Kindwall-Keller, T. L., Klimek, V. M., Pease, D. F., Steensma, D. P., Waldman, B. M., Horowitz, M. M., Burns, L. J., and Khera, N., “Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation.”, Cancer, vol. 127, no. 23, pp. 4339-4347, 2021.
S. M. Devine and Horowitz, M. M., “Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.”, J Clin Oncol, vol. 39, no. 5, pp. 534-544, 2021.
E. J. Fuchs, O'Donnell, P. V., Eapen, M., Logan, B., Antin, J. H., Dawson, P., Devine, S., Horowitz, M. M., Horwitz, M. E., Karanes, C., Leifer, E., Magenau, J. M., McGuirk, J. P., Morris, L. E., Rezvani, A. R., Jones, R. J., and Brunstein, C. G., “Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.”, Blood, vol. 137, no. 3, pp. 420-428, 2021.
C. G. Brunstein, DeFor, T. E., Fuchs, E. J., Karanes, C., McGuirk, J. P., Rezvani, A. R., Eapen, M., O'Donnell, P. V., and Weisdorf, D. J., “Engraftment of Double Cord Blood Transplantation after Nonmyeloablative Conditioning with Escalated Total Body Irradiation Dosing to Facilitate Engraftment in Immunocompetent Patients.”, Transplant Cell Ther, vol. 27, no. 10, pp. 879.e1-879.e3, 2021.
N. Farhadfar, Burns, L. J., Mupfudze, T., Shaw, B. E., Bollard, C. M., Devine, S. M., Horowitz, M. M., Jones, R. J., Murthy, H. S., Wingard, J. R., and Lee, S. J., “Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023.”, Transplant Cell Ther, vol. 27, no. 2, pp. 183.e1-183.e7, 2021.
P. Shindiapina, Pietrzak, M., Seweryn, M., McLaughlin, E., Zhang, X., Makowski, M., Ahmed, E. Hassan, Schlotter, S., Pearson, R., Kitzler, R., Mozhenkova, A., Le-Rademacher, J., Little, R. F., Akpek, G., Ayala, E., Devine, S. M., Kaplan, L. D., Noy, A., Popat, U. R., Hsu, J. W., Morris, L. E., Mendizabal, A. M., Krishnan, A., Wachsman, W., Williams, N., Sharma, N., Hofmeister, C. C., Forman, S. J., Navarro, W. H., Alvarnas, J. C., Ambinder, R. F., Lozanski, G., and Baiocchi, R. A., “Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial.”, Front Immunol, vol. 12, p. 700045, 2021.
J. R. Wingard, Alexander, B. D., Baden, L. R., Chen, M., Sugrue, M. W., Leather, H. L., Caliendo, A. M., Clancy, C. J., Denning, D. W., Marty, F. M., M Nguyen, H., L Wheat, J., Logan, B. R., Horowitz, M. M., and Marr, K. A., “Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?”, Open Forum Infect Dis, vol. 8, no. 10, p. ofab441, 2021.
L. W. Dillon, Gui, G., Logan, B. R., Fei, M., Ghannam, J., Li, Y., Licon, A., Alyea, E. P., Bashey, A., Devine, S. M., Fernandez, H. F., Giralt, S., Hamadani, M., Howard, A., Maziarz, R. T., Porter, D. L., Warlick, E. D., Pasquini, M. C., Scott, B. L., Horwitz, M. E., H Deeg, J., and Hourigan, C. S., “Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome.”, JCO Precis Oncol, vol. 5, 2021.
L. J. Costa, Derman, B. A., Bal, S., Sidana, S., Chhabra, S., Silbermann, R., Ye, J. C., Cook, G., Cornell, R. F., Holstein, S. A., Shi, Q., Omel, J., Callander, N. S., Chng, W. Joo, Hungria, V., Maiolino, A., Stadtmauer, E., Giralt, S., Pasquini, M., Jakubowiak, A. J., Morgan, G. J., Krishnan, A., Jackson, G. H., Mohty, M., Mateos, M. Victoria, Dimopoulos, M. A., Facon, T., Spencer, A., San Miguel, J., Hari, P., Usmani, S. Z., Manier, S., McCarthy, P., Kumar, S., Gay, F., and Paiva, B., “International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.”, Leukemia, vol. 35, no. 1, pp. 18-30, 2021.
G. Meyers, Hamadani, M., Martens, M., Ali, H., Choe, H., Dawson, P., Harris, A. C., van Hooren, E., Klaassen, W., Leifer, E., MacMillan, M. L., van Oosterhout, Y., Perez, L., Pusic, I., Vo, P., and Levine, J. E., “Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD.”, Bone Marrow Transplant, vol. 57, no. 2, pp. 302-303, 2021.
B. L. Scott, Pasquini, M. C., Fei, M., Fraser, R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E., Fernandez, H. F., Soiffer, R. J., Alyea, E., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Hourigan, C. S., Gui, G., Mendizabal, A., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., “Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.”, Transplant Cell Ther, vol. 27, no. 6, pp. 483.e1-483.e6, 2021.
H. T. Kim, Logan, B., and Weisdorf, D. J., “Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation.”, Transplant Cell Ther, vol. 27, no. 8, pp. 650-657, 2021.
L. Luznik, Pasquini, M. C., Logan, B., Soiffer, R. J., Wu, J., Devine, S. M., Geller, N., Giralt, S., Heslop, H. E., Horowitz, M. M., Jones, R. J., Litzow, M. R., Mendizabal, A., Muffly, L., Nemecek, E. R., O'Donnell, L., O'Reilly, R. J., Palencia, R., Schetelig, J., Shune, L., Solomon, S. R., Vasu, S., Ho, V. T., and Perales, M. - A., “Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.”, J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2021.
P. V. O'Donnell, Brunstein, C. G., Fuchs, E. J., Zhang, M. - J., Allbee-Johnson, M., Antin, J. H., Leifer, E. S., Elmariah, H., Grunwald, M. R., Hashmi, H., Horowitz, M. M., Magenau, J. M., Majhail, N., Milano, F., Morris, L. E., Rezvani, A. R., McGuirk, J. P., Jones, R. J., and Eapen, M., “Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes.”, Transplant Cell Ther, vol. 28, no. 2, pp. 109.e1-109.e8, 2021.
M. J. Martens and Logan, B. R., “A unified approach to sample size and power determination for testing parameters in generalized linear and time-to-event regression models.”, Stat Med, vol. 40, no. 5, pp. 1121-1132, 2021.
B. C. Tilley, Mainous, A. G., Amorrortu, R. P., M McKee, D., Smith, D. W., Li, R., DeSantis, S. M., Vernon, S. W., Koch, G., Ford, M. E., Diaz, V., and Alvidrez, J., “Using increased trust in medical researchers to increase minority recruitment: The RECRUIT cluster randomized clinical trial.”, Contemp Clin Trials, vol. 109, p. 106519, 2021.
2020
O. Shah, Tamaresis, J. S., Kenyon, L. Jean, Xu, L., Zheng, P., Gupta, P., Rangarajan, K., Lee, S., Spellman, S., Nikiforow, S., Zehnder, J., and Meyer, E. H., “Analysis of the Whole CDR3 T Cell Receptor Repertoire after Hematopoietic Stem Cell Transplantation in 2 Clinical Cohorts.”, Biol Blood Marrow Transplant, vol. 26, no. 6, pp. 1050-1070, 2020.
J. Pidala, Martens, M., Anasetti, C., Carreras, J., Horowitz, M., Lee, S. J., Antin, J., Cutler, C., and Logan, B., “Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation.”, JAMA Oncol, vol. 6, no. 1, p. e192974, 2020.
L. F. Newell, DeFor, T. E., Cutler, C., Verneris, M. R., Blazar, B. R., Miller, J. S., Antin, J. H., Howard, A., Wu, J., MacMillan, M. L., Panoskaltsis-Mortari, A., Weisdorf, D. J., and Holtan, S. G., “Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.”, Biol Blood Marrow Transplant, vol. 26, no. 3, pp. 606-611, 2020.
M. J. Martens and Logan, B. R., “Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point.”, Lifetime Data Anal, vol. 26, no. 3, pp. 603-623, 2020.
C. S. Hourigan, Dillon, L. W., Gui, G., Logan, B. R., Fei, M., Ghannam, J., Li, Y., Licon, A., Alyea, E. P., Bashey, A., H Deeg, J., Devine, S. M., Fernandez, H. F., Giralt, S., Hamadani, M., Howard, A., Maziarz, R. T., Porter, D. L., Scott, B. L., Warlick, E. D., Pasquini, M. C., and Horwitz, M. E., “Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.”, J Clin Oncol, vol. 38, no. 12, pp. 1273-1283, 2020.
L. J. Costa, Iacobelli, S., Pasquini, M. C., Modi, R., Giaccone, L., Blade, J., Schonland, S., Evangelista, A., Perez-Simon, J. A., Hari, P., Brown, E. E., Giralt, S. A., Patriarca, F., Stadtmauer, E. A., Rosinol, L., Krishnan, A. Y., Gahrton, G., and Bruno, B., “Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation.”, Bone Marrow Transplant, vol. 55, no. 9, pp. 1810-1816, 2020.
Z. DeFilipp, Burns, L. J., Jaglowski, S. M., Leppin, A. L., Pavletic, S., Waldman, B., Weisdorf, D. J., Wood, W. A., and Khera, N., “A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703.”, Biol Blood Marrow Transplant, vol. 26, no. 12, pp. e305-e308, 2020.
J. E. Levine, Antin, J. H., Allen, C. E., Burroughs, L. M., Cooke, K. R., Devine, S., Heslop, H., Nakamura, R., Talano, J. An, Yanik, G., and DiFronzo, N., “Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.”, Biol Blood Marrow Transplant, vol. 26, no. 5, pp. e94-e100, 2020.